Our Portfolio

Orphan Disease Treatment Institute Co., Ltd.

Outline Development of therapeutic agent for Duchenne muscular dystrophy with ENA oligonucleotides
as the active ingredient
Industry Health/medicine
Commercialization stage Early stage

Provided Support

  • Make effective use of patents and technologies from academia that have fallen into “the devil’s river” between baseline research and development research, and provide a bridge to pharmaceutical companies
  • Provide momentum for Japanese pharmaceutical companies to become more aggressive in development of orphan drugs
  • Pump-prime private VC investment in orphan drug technologies
Authorized Investment ¥2,010 million (maximum)
Investment Structure
HOME
About Us
Our Business
Newsroom
Our Investments